Read by QxMD icon Read

Cryoablation for renal cell cancer

Miltiadis E Krokidis, Panagiotis Kitrou, Stavros Spiliopoulos, Dimitrios Karnabatidis, Konstantinos Katsanos
Surgical partial nephrectomy is still considered as the "gold standard" for the definitive management of small malignant renal masses, whereas treatment with image-guided percutaneous ablation is still mainly reserved for those patients who cannot undergo nephron-sparing surgical resection due to advanced age, underlying comorbidities or compromised renal function. Nonetheless, the recent evidence that underlines the long-term oncological equipoise of percutaneous ablation methods with surgical resection in combination with the reduced complication rate and cost supports the use of an image-guided minimally invasive approach as a first-line treatment...
April 6, 2018: Insights Into Imaging
M C Kriegmair, N Wagener, S J Diehl, N Rathmann
Renal cell cancer is nowadays predominantly diagnosed in early stages due to the widespread use of sectional imaging for unrelated symptoms. Small renal masses (<4 cm) feature a largely indolent biology with a very low risk for metastasis or even a benign biology in up to 30% of the cases. Consequently, there is a need for less invasive therapeutic alternatives to nephron-sparing surgery. Meanwhile, there is a broad portfolio of local ablation techniques to treat small renal tumors. These include the extensively studied radiofrequency ablation and cryoablation techniques as well as newer modalities like microwave ablation and irreversible electroporation as more experimental techniques...
February 2, 2018: Der Urologe. Ausg. A
Alessia Mennitto, Elena Verzoni, Paolo Grassi, Raffaele Ratta, Giovanni Fucà, Giuseppe Procopio
in the last decades, the treatment of renal cell carcinoma has become more complex due to the introduction of novel systemic agents and the improvement of the loco-regional therapies that prolong survival maintaining a good quality of life. Areas covered: in this review, we summarize the currently available local and systemic treatment options, their indications and their hypothetical role in the management of advanced renal cell carcinoma, highlighting the need of multimodality treatment paradigms within interdisciplinary decision-making...
December 2017: Expert Review of Clinical Pharmacology
Nathan E Frenk, Dania Daye, Kemal Tuncali, Ronald S Arellano, Paul B Shyn, Stuart G Silverman, Florian J Fintelmann, Raul N Uppot
PURPOSE: To evaluate local control and survival after image-guided ablation of adrenal gland metastases. MATERIALS AND METHODS: Image-guided ablations of adrenal metastases measuring < 5 cm performed at 2 academic medical centers between July 2002 and June 2016 were analyzed. There were 51 procedures performed on 46 tumors (mean diameter 2.8 cm ± 1.1; range, 0.7-4.9 cm) in 38 patients (mean age 66 y; range, 41-80 y) with renal cell carcinoma (n = 17 patients; 45%), non-small cell lung cancer (n = 10 patients; 26%), and other primary malignancies (n = 11 patients; 29%)...
February 2018: Journal of Vascular and Interventional Radiology: JVIR
Keiichi Ito, Shigeyoshi Soga, Kenji Seguchi, Yusuke Shinchi, Ayako Masunaga, Shinsuke Tasaki, Kenji Kuroda, Akinori Sato, Junichi Asakuma, Akio Horiguchi, Hiroshi Shinmoto, Tatsumi Kaji, Tomohiko Asano
Partial nephrectomy is the treatment of choice for small renal cell carcinoma (RCC) from the perspective of cancer management and renal function. However, when patients with RCC are of advanced age, exhibit severe comorbidities, including cardiovascular and pulmonary diseases, or have hereditary RCC, ablative therapies, including radiofrequency ablation (RFA) and cryoablation are useful treatment options. In the present study, the clinical outcomes of percutaneous RFA for treating small RCC were evaluated. Between December 2005 and March 2015, 40 patients (41 renal tumors in total) underwent RFA and a total of 50 sessions of RFA were performed...
July 2017: Oncology Letters
Atsushi Takamoto, Motoo Araki, Koichiro Wada, Morito Sugimoto, Yasuyuki Kobayashi, Katsumi Sasaki, Toyohiko Watanabe, Yasutomo Nasu
We report the case of a 58-year-old Japanese man with bilateral synchronous renal cell carcinoma (RCC). The diameters of the right and left tumors were 56 and 69 mm, respectively. Both tumors were endophytic. Cryoablation with prophylactic embolization was performed for the left tumor, and 1 month later, a right open partial nephrectomy was performed. No recurrence was observed during a 16-month follow-up, and the serum creatinine level has been stable. The prognosis of bilateral synchronous RCC is better than that of dialysis patients...
April 2017: Acta Medica Okayama
Max Meng
PURPOSE: With the incidence of renal cell carcinoma on the rise treatment options for the small renal mass have broadened. Cryoablation is increasingly used as a therapeutic option for renal tumors in select cases. However, studies with long-term oncologic outcomes are sparse. We evaluated the long-term oncologic outcomes of laparoscopic renal mass cryoablation. MATERIALS AND METHODS: We reviewed our laparoscopic cryoablation database for patients treated with laparoscopic cryoablation from October 1997 to February 2005...
May 2017: Urologic Oncology
Mao Lin, Kecheng Xu, Shuzhen Liang, Xiaohua Wang, Yinqing Liang, Mingjie Zhang, Jibing Chen, LiZhi Niu
In this study, the clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for advanced renal cell cancer was evaluated. From July to December 2016, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n=30); and (2) the cryoablation combined with allogenic NK cells group (n=30). The clinical efficacy, quality of life, immune function, and other related indicators were evaluated. Combining allogeneic NK cells with cryoablation had a synergistic effect, not only enhancing the immune function and improving the quality of life of the patients, but also significantly exhibiting good clinical efficacy of the patients...
April 2017: Immunology Letters
C M Sommer, D F Vollherbst, G M Richter, H U Kauczor, P L Pereira
CLINICAL/METHODICAL ISSUE: In the treatment of localized renal cell carcinoma, the lack of randomization in controlled trials on thermal ablation is a major limitation. The latter leads to significant study bias and it ultimately remains unclear whether the improved overall survival in favor of partial nephrectomy can actually be attributed to the treatment method. STANDARD RADIOLOGICAL METHODS: For T1a (≤4 cm) renal cell carcinoma without lymph node and distant metastases, excellent technical and clinical results have been described after imaging-guided radiofrequency ablation and cryoablation...
February 2017: Der Radiologe
Jeremy W Martin, Roshan M Patel, Zhamshid Okhunov, Aashay Vyas, Duane Vajgrt, Ralph V Clayman
INTRODUCTION: Cryoablation (CA) is a minimally invasive modality for the management of small renal cortical neoplasms (RCN). Effective ablation is dependent on achieving target temperatures during CA that result in tumor cell death. We investigated long-term oncologic outcomes following CA using multipoint thermal sensors (MTS), which allow precise temperature determination at four points along the needle. METHODS: We performed a retrospective review of 20 patients with <4 cm RCN who underwent de novo CA from 2005 to 2009...
April 2017: Journal of Endourology
Eisuke Tomiyama, Shinichiro Fukuhara, Takeshi Ujike, Akira Nagahara, Motohide Uemura, Hiroshi Kiuchi, Ryoichi Imamura, Yasushi Miyagawa, Mikio Nin, Norio Nonomura
We report a case of recurrent renal cancer in the autografted kidney, treated with percutaneous cryoablation. A 59-year-old man who had bilateral renal tumors underwent radical left nephrectomy, ex vivo right partial nephrectomy and auto-transplantation at the right ileal fossa in our hospital 11 years ago. Histopathological examination showed clear cell renal cell carcinoma in bilateral kidneys (pT1bN0M0). He had been followed at another hospital without tumor recurrence for 11 years. In 2014, an enhanced CT scan revealed a renal tumor with a diameter of two centimeters in the autografted kidney, which was thought to be a recurrence of the initial renal cancer...
October 2016: Hinyokika Kiyo. Acta Urologica Japonica
S Brandon Hancock, Christos S Georgiades
The number of new cases of renal cell carcinoma has been steadily increasing since the 1960s, reaching 62,000 and 89,000 annually in the United States and Europe, respectively, in 2016. The current standard of care for early-stage disease is nephron-sparing surgery, which has a demonstrated long-term disease-free survival and an acceptable safety profile. Technical developments (thin, powerful probes and real-time image guidance systems) have allowed image-guided percutaneous ablation to become a viable option for stage I renal cell carcinoma...
November 2016: Cancer Journal
Alessia Mennitto, Elena Verzoni, Giuseppina Calareso, Carlo Spreafico, Giuseppe Procopio
Renal cell carcinoma (RCC) is the 10th most common cancer in Western countries. The prognosis of metastatic disease is unfavorable but may be different according to several risk factors, such as histology and clinical features (Karnofsky performance status, time from nephrectomy, hemoglobin level, neutrophils and thrombocytes count, lactate dehydrogenase and calcium serum value, sites and extension of the disease). In this review, we focused on some recent developments in the use of immunotherapy, surgery and cryotherapy in the treatment of advanced disease...
January 21, 2017: Tumori
Peter A Caputo, Homayoun Zargar, Daniel Ramirez, Hiury S Andrade, Oktay Akca, Tianming Gao, Jihad H Kaouk
BACKGROUND: The traditional treatment for a cT1b renal tumor has been radical nephrectomy. However, recent guidelines have shifted towards partial nephrectomy (PN) in selected patients with cT1b renal tumors. Furthermore, practitioners have extended the role of cryoablation (CA) to treat cT1b tumors in selected patients. OBJECTIVE: To evaluate the efficacy of CA compared to PN for cT1b renal tumors. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective review of patients who underwent either renal CA (laparoscopic or percutaneous) or PN (robot-assisted) for a cT1b renal mass (>4cm and ≤7cm) between November 1999 and August 2014...
January 2017: European Urology
Lasse L Nonboe, Tommy K Nielsen, Søren Høyer, Ole Graumann, Jørgen Frøkiær, Michael Borre
INTRODUCTION: The minimally invasive treatment of small renal masses with cryoablation has become increasingly widespread during the past 15 years. Studies with long-term follow-up are beginning to emerge, showing good oncological control, however, tumors with a central and endophytic location seem to possess an increased risk of treatment failure. Such tumors are likely to be subjected to a high volume of blood giving thermal protection to the cancerous cells. Arterial clamping during freezing might reduce this effect but at the same time subject the kidney to ischemia...
August 2017: Technology in Cancer Research & Treatment
P J Zondervan, M Buijs, J J de la Rosette, O van Delden, K van Lienden, M P Laguna
INTRODUCTION: Cryoablation (CA) has been broadly used mostly in the treatment of small renal masses (SRMs). The present review aims to define the current role of CA in the treatment of SRMs by assessing clinical indications and outcomes. METHOD: A comprehensive review on patient selection, procedural details, perioperative complications, and short/long-term oncological and functional outcomes was conducted. For each section, a take-home message was formulated with level of evidence (LoE) according to Cochrane collaboration...
December 2016: International Journal of Surgery
Zhamshid Okhunov, Joshua Chamberlin, Daniel M Moreira, Arvin George, Kara Babaian, Paras Shah, Ramy Youssef, Kamaljot S Kaler, Igor I Lobko, Louis Kavoussi, Jaime Landman
BACKGROUND: The management of locally recurrent renal-cell carcinoma (RCC) following cryoablation remains a clinical dilemma. There is limited data regarding the management of locally recurrent disease in the setting of patients who have failed initial percutaneous cryoablation (PCA). We evaluate and report our experience with salvage PCA for local recurrence following renal cryoablation failure. PATIENTS AND METHODS: We reviewed our experience with patients who underwent salvage PCA for local biopsy proven RCC recurrence following primary cryoablation procedures...
June 2016: Journal of Endourology
Florian J Fintelmann, Kemal Tuncali, Stefan Puchner, Debra A Gervais, Ashraf Thabet, Paul B Shyn, Ronald S Arellano, Servet Tatli, Peter R Mueller, Stuart G Silverman, Raul N Uppot
PURPOSE: To identify retrospectively predictors of catecholamine surge during image-guided ablation of metastases to the adrenal gland. MATERIALS AND METHODS: Between 2001 and 2014, 57 patients (39 men, 18 women; mean age, 65 y ± 10; age range, 41-81 y) at two academic medical centers underwent ablation of 64 metastatic adrenal tumors from renal cell carcinoma (n = 27), lung cancer (n = 23), melanoma (n = 4), colorectal cancer (n = 3), and other tumors (n = 7)...
March 2016: Journal of Vascular and Interventional Radiology: JVIR
Carlo Magno, Giuseppe Mucciardi, Alessandro Galì, Rosa Pappalardo, Francesco Lembo, Giuseppina Anastasi, Salvatore Butticè, Giorgio Ascenti, Franco Lugnani
OBJECTIVES: Locally advanced prostate cancer may cause several complications such as haematuria, bladder outlet obstruction, and renal failure due to the ureteral obstruction. Various treatments have been suggested, including radiotherapy, antifibrinolytics, bladder irrigation with alum solution, transurethral surgery and angioembolization, none of which have proven effectiveness. In the last years cryoablation has become a valid therapeutic option for prostate cancer. In our experience we used this 'new' technique as haemostatic therapy...
October 2015: Therapeutic Advances in Urology
Matthew J Maurice, Hui Zhu, Jonathan E Kiechle, Simon P Kim, Robert Abouassaly
OBJECTIVE: To describe recent temporal trends in biopsy use for renal cell carcinoma and to identify factors associated with biopsy. MATERIALS AND METHODS: Renal cell carcinoma diagnoses from 2003 to 2011 were identified using the National Cancer Data Base. Cases were classified by traditional (clinical stage T4, N1, or M1, or history of other malignancies) or expanded biopsy indications. Time trends were plotted, and multivariate analysis was performed to identify factors associated with biopsy...
November 2015: Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"